HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

BMS’ Sotyktu secures EC approval for psoriatic arthritis

BMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic arthritis (PsA).

By Pharmaceutical Technology · May 11, 2026 · via Pharmaceutical Technology
BMS’ Sotyktu secures EC approval for psoriatic arthritis

Image: Pharmaceutical Technology

This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →

Tags
pipelineformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
PipelineFiercePharma ↗
FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
After a surprise rejection in January, the FDA has agreed to reconsider a T-cell therapy based on the same sin…
May 10, 2026
Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis
PipelineFierceBiotech ↗
Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis
Entrada Therapeutics’ Duchenne muscular dystrophy data have fallen well short of expectations, crashing the bi…
May 9, 2026
Entrada stock falls on Duchenne data; Wegovy expands access
PipelineEndpoints News ↗
Entrada stock falls on Duchenne data; Wegovy expands access
Plus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial…
May 7, 2026